Screener
Immunome IMNM EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Immunome’s reported figures.
The source filing: Immunome’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
FAQ
- What is Immunome's EBITDA?
- Immunome (IMNM) reported EBITDA of -$58.73M in Q1 2026.
- How has Immunome's EBITDA changed year-over-year?
- Immunome's EBITDA decreased by 33.4% year-over-year, from -$44.03M to -$58.73M.
- What is the long-term trend for Immunome's EBITDA?
- Over 4 years (2021 to 2025), Immunome's EBITDA has grown at a 73.5% compound annual growth rate (CAGR), from -$24.45M to -$221.65M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Immunome's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude